ePathScreen
L.B. Dahle purchased software from a highly skilled student at a prestigious university that allows Pathologists to identify abnormal/cancerous cells by reading digitized slides with greater accuracy and speed. The software is being modified for a very important FDA trial, which will greatly enhance the value of the software and LB’s company, ePathScreen. At the same time, he is trying to understand the buying behavior of pathology labs, as well as the features that will foster early adoption in the pathology market place. Through discussions with his TAB Peer Group, LB was referred to a retired business owner with expertise that has greatly expanded his understanding of the user market for his AI diagnostic software. The result of this introduction is that ePathScreen now has an advisor that has sold to the pathology lab community for many years. She has also identified additional market opportunities for the software that is presently being further developed and tested.